WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002003997) PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/003997    International Application No.:    PCT/US2001/041242
Publication Date: 17.01.2002 International Filing Date: 03.07.2001
Chapter 2 Demand Filed:    30.01.2002    
IPC:
C07H 19/04 (2006.01)
Applicants: RIBAPHARM INC. [US/US]; 3300 Hyland Avenue, Costa Mesa, CA 92626 (US) (For All Designated States Except US).
WANG, Guangyi [CN/US]; (US) (For US Only).
GIRARDET, Jean-Luc [FR/US]; (US) (For US Only).
GUNIC, Esmir [US/US]; (US) (For US Only).
LAU, Johnson [US/US]; (US) (For US Only).
PIETRZKOWSKI, Zbigniew [PL/US]; (US) (For US Only).
HONG, Zhi [US/US]; (US) (For US Only)
Inventors: WANG, Guangyi; (US).
GIRARDET, Jean-Luc; (US).
GUNIC, Esmir; (US).
LAU, Johnson; (US).
PIETRZKOWSKI, Zbigniew; (US).
HONG, Zhi; (US)
Agent: RUTAN & TUCKER, LLP; P.O. Box 1950, Costa Mesa, CA 92628-1950 (US)
Priority Data:
60/216,418 06.07.2000 US
Title (EN) PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES
(FR) NUCLEOSIDES DE PYRIDO[2,3-D]PYRIMIDINE ET DE PYRIMIDO[4,5-D]PYRIMIDINE
Abstract: front page image
(EN)A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2', C3', C4' and/or C5' position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.
(FR)Analogue nucléoside de purine comprenant une pyrido[2,3-d]pyrimidine ou une pyrimido[4,5-d]pyrimidine ainsi qu'une entité sucre modifiée, le cas échéant, en position C2', C3', C4' et/ou C5' position. Des composés plus particulièrement considérés comprennent également des formes de promédicaments d'analogues nucléosides de la purine ; les analogues nucléosides de la purine et les promédicaments correspondants sont employés dans la réduction de la croissance de cellules néoplastiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)